CARDIOQUIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cardioquin, and when can generic versions of Cardioquin launch?
Cardioquin is a drug marketed by Pharm Res Assoc and is included in one NDA.
The generic ingredient in CARDIOQUIN is quinidine polygalacturonate. There are twenty-seven drug master file entries for this compound. Additional details are available on the quinidine polygalacturonate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CARDIOQUIN?
- What are the global sales for CARDIOQUIN?
- What is Average Wholesale Price for CARDIOQUIN?
Summary for CARDIOQUIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| DailyMed Link: | CARDIOQUIN at DailyMed |
US Patents and Regulatory Information for CARDIOQUIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharm Res Assoc | CARDIOQUIN | quinidine polygalacturonate | TABLET;ORAL | 011642-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
